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Abstract 
Background: Lipodystrophy (LD) is a frequent adverse event of combination antiretroviral therapy (ART) and occurs 
mainly in patients exposed to first‑generation antiretroviral drugs. The aim of this study was to explore and measure 
the interaction between LD, mental health, and quality of life of human immunodeficiency virus (HIV) positive indi‑
viduals seen in a metabolic clinic.
Methods: We conducted a single‑site cross‑sectional study including all HIV‑infected patients attending the LIPO 
group and metabolism day clinic at the University Hospitals of Geneva, Switzerland between January 31, 2008 and 
November 28, 2013. Data on LD were prospectively collected using the HIV Outpatient Study (HOPS) score, the Lipod‑
ystrophy Case Definition (LDCD), ART regimens, anthropometric measures, imaging, and standardized questionnaires. 
Quality of life was evaluated using a visual analog scale of 0–100. Depression and anxiety were assessed using the 
Beck Depression Inventory and the State Trait Anxiety Inventory scales, respectively.
Results: One hundred ninety‑four patients (54.6% male; 45.4% female; median age, 50 years) on successful ART 
(median CD4 cell count, 569.0 cells/mm3; median viral load, 20 copies/mL) were evaluated. Among these, 62.7, 63.5 
and 35.5% of patients reported at least one body site affected by fat hypertrophy, atrophy or both, respectively. Using 
the LDCD score conservative definition, including imaging and biological values, 57.8% were diagnosed with LD. Of 
these, 39.7% suffered from severe/very severe LD. Depression was reported by 35.6% of individuals; 51.9% had anxi‑
ety symptoms and 49.5% reported poor quality of life (defined as being inferior to 50% on a scale from 0 to 100%). 
LD (odds ratio (OR = 5.22, 95% confidence interval (CI) 1.07–25.37, p‑value: 0.040), depression (OR = 4.67, 95% CI 
1.08–20.31, p‑value 0.040), and anxiety (OR = 7.83, 95% CI 1.91–32.03, p‑value 0.004) all affected significantly the qual‑
ity of life.
Conclusions: LD, depression and anxiety were frequent features among HIV‑infected individuals seen in the meta‑
bolic clinic and significantly impacted on their quality of life.
Keywords: HIV infection, Lipodystrophy, Lipohypertrophy, Lipoatrophy, Quality of life, Mental health disorder, 
Depression, Anxiety
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Background
Since the description of the first case of acquired 
immune deficiency syndrome (AIDS) in 1981, human 
immunodeficiency virus (HIV) infection has reached 
pandemic proportions and has continued to expand 
in worldwide; in 2012 an estimated of 35.3 million of 
peoples were infected by HIV [1]. Nucleoside reverse 
transcriptase inhibitors (NRTIs), followed by protease 
inhibitors (PIs), were the first antiretroviral (ARV) 
drugs used to treat HIV [2] and succeeded in decreasing 
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mortality by an estimated of 4.2 million of deaths dur-
ing the previous decade [1, 3, 4]. However, this thera-
peutic revolution was not without complications as 
multiple side-effects were associated with these first-
generation ARV drugs. Among these, lipodystrophy (LD) 
was highlighted in 1998 by Carr et al. [5]. This syndrome 
comprises three phenotypes: lipohypertrophy (LH); 
lipoatrophy (LA); or a mixed pattern of both [5, 6]. LD 
can be associated also with metabolic disorders, there-
fore increasing the risk of cardiovascular disease [7].
There is currently no universal definition of LD. This 
implies significant variation in the prevalence rate, inci-
dence, severity, and risk factors, which makes difficult 
any comparison between studies and across countries 
and ethnicities [7]. Diagnosis is based mainly on clini-
cal observations by the patients themselves and by the 
physicians. To help meeting this challenge, the HIV 
Outpatients Study (HOPS) scale provides a subjective, 
but standardized LD evaluation using specific questions 
related to the clinical signs of the disorder [8]. Carr et al. 
developed a score in order to offer a more objective defi-
nition of LD, the Lipodystrophy Case Definition (LDCD), 
with a reported 79% sensitivity and 80% specificity [9, 
10]. Nevertheless, this score does not allow differentiat-
ing between disease phenotypes [6].
Systematic reviews have discussed the impact of ARV 
agents and regimens on LD, but with discordant conclu-
sions. If a clear relationship between NRTIs (thymidine 
analogs) and LA has been demonstrated, the causal role 
of specific drugs in the development of fat accumulation 
remains to be clarified [11, 12]. With the advent of newer 
drugs and the earlier detection of HIV, the prevalence of 
LD is now decreasing [11], although 48  weeks after the 
tests of a novel, potent NRTI, BMS-986001 a peripheral 
and central fat accumulation was observed [13]. However, 
the overall prevalence of LD remains high as many patients 
were exposed to first-generation molecules and damage 
caused to adipose tissue has only limited reversibility [14].
Several research groups have focused on the impact of 
LD on quality of life [15–23]. In addition, these reports 
have described discrepant results and conclusions 
regarding the interplay with mental health disorders, 
such as depression or anxiety [24–28].
This study aimed to identify the complex relationships 
between LD, mental health disorders, and the quality of 
life in patients attending the LIPO group and metabo-




All patients participating to the metabolic clinic (LIPO 
group and metabolism) at the University Hospitals of 
Geneva between January 31, 2008 and November 28, 
2013 were included in the study. This multidisciplinary 
consultation (day hospital) is held once monthly and 
patients are referred to the clinic by their treating physi-
cian for several reasons, such as the evaluation of HIV-
related or unrelated multiple medical co-morbidities, or 
LD management. A complete medical check-up is coor-
dinated by the infectious diseases team and includes 
blood analyses, imaging [body composition and bone 
dual-energy X-ray absorptiometry (DXA), and thoracic 
vertebral level (T12) as well as lumbar vertebral level (L5) 
computed tomography (CT) single slice scans], and psy-
chological, plastic surgery, dermatology, endocrinology, 
bone diseases and dietary consultations. Physicians from 
other medical specialties are available upon request e.g., 
nephrologist, endocrinologist, bone specialist, cardiolo-
gist, hepatologist. All patients provided written informed 
consent and the study protocol was approved by the 
clinical ethics committee of the University Hospitals of 
Geneva (CER #09017).
Definitions
LD Patients and physicians both completed a question-
naire based on the HOPS scale [8]. Different parts of the 
patient body (arms, legs, cheeks and buttocks for signs 
of atrophy; abdomen, neck and breast for signs of hyper-
trophy) were evaluated and described as absent, subtle, 
moderate or severe. The different values were then strati-
fied into five categories (none, all subtle, subtle/moderate, 
one severe, two or more severe). According to Lichten-
stein et al. [8], this score was then classified in two strata; 
absent vs present and used like this in all the statistical 
analysis.
We used also the complete model of LDCD score, 
developed by Carr et  al. and validated in a large cohort 
of patients [9], to determine the categories used to define 
the presence of LD [10]. LD was stratified in four classes, 
from very subtle/absent (<0 to 9.9 points) to severe/very 
severe (15 to >23 points). This score was then classified in 
two classes; absent (subtle/absent, subtle, moderate) ver-
sus present (severe/very severe) and used like this for all 
the statistical analysis. These definitions are presented in 
the Additional file 1: Table S1.
Quality of life Patients were asked by a trained psy-
chologist to score their perceived quality of life on a 
20  cm quantitative scale ranging from 0 to 100%. Zero 
corresponds to the “worst possible quality of life” and 
100 to the “best possible quality of life”. This measure is 
often used in cognitive behavioral therapy and is a part 
of a wider score validated in different studies [29]. In our 
study, we used the short version of the score. Patients 
were classified as having a low (0–50%) or high quality of 
life (51–100%).
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Anxiety was evaluated by a trained psychologist using 
the State Trait Anxiety Inventory (STAI Y-B) grading by 
a questionnaire with 20 items regarding the trait anxi-
ety developed by Spielberger in 1983 [30]. A score equal 
or greater than 46 indicated the presence of anxiety 
symptoms.
Depression was measured by a trained psychologist 
using the Beck Depression Inventory (BDI) score [31], 
including a questionnaire with 21 items. Patients were 
considered to have depression when the score was above 
19.
The waist was measured halfway between the last rib 
and the iliac crest, and the hips by the maximal buttock 
circumference.
Imaging studies
A CT-scan consisting of two single slices of 6 mm thick-
ness each obtained at the T12 and L5 level was performed 
in each patient in order to calculate the ratio between the 
visceral adipose tissue and the subcutaneous adipose tis-
sue (VAT/SAT). Abdominal VAT and SAT were meas-
ures by contouring manually the areas with attenuation 
values of adipose tissue (range 190 Hounsfield Units to 30 
Hounsfield Units) according to the literature [32]. Limb 
as well as leg fat measurement, both needed for LDCD 
score calculation, was obtained by Total Body Dual X Ray 
Absorbsometry (DXA) on a Discovery A Bone densitom-
eter (Hologic Inc. Bedford, MA, USA). Total body scans 
were performed by DXA (Dual X Ray Absorbsometry) 
using the same Discovery A Bone densitometer all over 
the study period (Hologic Inc. Bedford, MA, USA). To 
assure reliability and stability of our device, Phantom was 
scanned daily; QC (quality control) data plot was verified 
online by a secured, centralized database program. ISCD 
(International Society of Clinical Densitometry) recom-
mendations for precision assessment, scans acquisition 
and analysis are applied.
Statistical analyses
We used a kappa test with an alpha threshold of 5% to 
measure the level of agreement between patients and 
physicians regarding the presence of fat loss or accumu-
lation by using the HOPS score. A Chi-square test with 
an alpha threshold of 5% was used to verify if gender had 
an impact on qualitative variables (depression, anxiety, 
quality of life, and LDCD). We conducted a multivari-
ate logistic regression model to identify risk factors for a 
low quality of life, including the severe LD (LDCD) vari-
able and all other variables with a p value lower than 0.2 
in the univariate model, to assess the specific contribu-
tion of severe LD (LDCD). To identify specific, poten-
tial confounding risk factors of quality of life, such as 
depression and anxiety, we developed an additional 
model including clinical risk factors considered to have 
a potential impact on quality of life in HIV population: 
age; gender; severe LD (LDCD), atrophy and hypertrophy 
observed by patients and physicians (HOPS); body mass 
index (≥30  kg/m2); HIV duration (≥10  years); United 
States Centers for Disease Control and Prevention HIV 
stage (B&C); CD4 count (≤300 cells/mm3); and HIV viral 
load (≥40 copy/mL). Finally, we performed the Hosmer–
Lemeshow test, as well as the area under the ROC curve, 
to evaluate the overall fit of our two logistic regression 
models. Statistical analyses were carried out with STATA 
software, version 13.0 (StataCorp, College Station, TX, 
USA).
Results
Characteristics of the study population
One hundred ninety-four HIV+ individuals were 
included in the analysis median time since HIV diagnosis 
was 17 years and a median age of 50 years old [interquar-
tile range (IQR) 44.0–55.0]; 88 (45.4%) were female and 
108 (72.5%) were Caucasians (Table  1). Twenty patients 
(10.4%) were obese with a body mass index ≥30 kg/m2. 
Almost all patients (99.0%) were on antiretroviral ther-
apy with a majority (88.5%) on nucleoside reverse tran-
scriptase inhibitor (NRTI) treatment. Protease inhibitors 
(PIs) were used in 50.1% of the patients while 43.7% were 
taking non-nucleoside reverse transcriptase inhibitor 
(NNRTI). Among those, 36 (18.6%) were taking efavirenz 
(EFV), 34 (17.6%) on etravirine and 14 (7.2%) on nevirap-
ine. Eighty-six percent had a viral load below the thresh-
old of 40 copies/mL; median CD4 count was 569.0 cell/
mm3 (IQR: 403.0–710.0). Sixty-eight patients (35.6%) 
reported signs of depression (moderate 23.6%; severe 
12.0%). Of them, a psychiatric intervention was indicated 
in 89.0%, including a psychiatric evaluation in 22.9%, a 
psychopharmacologic treatment in 33.3%, and a psy-
chotherapeutic treatment in 65.6%. Ninety-nine patients 
(51.9%) were anxious (moderate 27.8%; severe 24.1%). A 
psychiatric intervention was indicated in 83.9% of those, 
including a psychiatric evaluation in 18.3%, a psychop-
harmacologic treatment in 29.6%, and a psychothera-
peutic treatment in 72.3%. However, we do not have the 
information on whether the patient came or not to his 
or her appointment. Finally, 93 (49.5%) mentioned poor 
quality of life (≤50%) (Table 1).
Prevalence of LD
The prevalence of LD signs and symptoms were assessed 
using both the LDCD [10] and HOPS scores [8] (Addi-
tional file 1: Table  S1). The LDCD score diagnosed LD 
among 57.8% individuals (from subtle to very severe 
LDCD score). Of these, 39.7% had imaging or biologi-
cal features corresponding to severe/very severe LD 
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Table 1 Characteristics of the study population
N missing All patients Quality of Lifea p-value
Poor (≤50% visual score) High (>50% visual score)
Median (IQR) Median (IQR) Median (IQR)
N = 194 N = 93 N = 95
Patient characteristics
 Sex female, n (%) 88.0 (45.4) 50 (53.8) 34 (35.8) 0.013*
 Age (years) 50.0 (44.0–55.0) 48.0 (43.0–52.0) 51.0 (45.0–59.0) 0.008*
 Ethnicity 45 0.005*
  Caucasians n (%) 108 (72.5) 42 (61.8) 62 (82.7)
  Africans n (%) 29 (19.5) 21 (30.9) 7 (9.3)
  Others n (%) 12 (8.0) 5 (7.3) 6 (8.0)
 Waist/hip ratio 9 0.9 (0.9–1.0) 0.9 (0.8–1.0) 0.9 (0.9–1.0) 0.105
 VAT/SAT ratiob,c 9 0.5 (0.3–1.0) 0.4 (0.2–0.7) 0.5 (0.3–1.1) 0.009*
 Body mass index (kg/m2)d 1 24.0 (22.0–27.0) 24.0 (22.0–27.0) 24.0 (22.0–26.0) 0.547
 Triglycerides (mmol/l) 1.3 (0.9–2.2) 1.2 (0.8–1.9) 1.4 (1.0–2.4) 0.252
 Total cholesterol (mmol/l) 5.1 (4.4–5.7) 5.0 (4.3–5.7) 5.1 (4.7–5.9) 0.105
 HDL cholesterol (mmol/l) 1.2 (0.9–1.4) 1.1 (0.9–1.4) 1.2 (0.9–1.4) 0.795
HIV characteristics
 HIV duration (years) 20 17.0 (11.0–22.0) 15.5 (10.0–21.0) 18.5 (12.0–22.0) 0.099
 CDC HIV stagee 14 0.362
  A, n (%) 85.0 (47.2) 36.0 (41.9) 46.0 (52.3)
  B, n (%) 33.0 (18.3) 16.0 (18.6) 15.0 (17.0)
  C, n (%) 62.0 (34.4) 34.0 (39.5) 27.0 (30.7)
 CD4 (cells/mm3) 4 569.0 (403.0–710.0) 612.0 (411.5–752.0) 533.5 (394.0–700.0) 0.116
 HIV viral load (copy/ml) 2 20.0 (20.0–40.0) 20.0 (20.0–40.0) 20 (20.0–40.0) 0.495
 Antiretroviral therapy, n (%) 192.0 (99.0) 92.0 (98.9) 94.0 (98.9) 0.988
  Protease inhibitors containing, n (%) 1 97.0 (50.5) 42.0 (46.1) 51.0 (54.3) 0.271
  Integrase inhibitor containing, n (%) 1 41.0 (21.3) 17.0 (18.7) 24.0 (25.5) 0.262
  NRTIe containing, n (%) 1 170.0 (88.5) 83.0 (91.2) 81.0 (86.2) 0.280
  NNRTIf containing, n (%) 1 84.0 (43.7) 42.0 (46.1) 41.0 (43.6) 0.729
  Efavirenz, n (%) 1 36.0 (18.6) 20.0 (22.0) 15.0 (16.0) 0.296
  Etravirine, n (%) 1 34.0 (17.6) 16.0 (17.6) 18.0 (19.1) 0.783
  Nevirapine, n (%) 1 14.0 (7.2) 6.0 (6.6) 8.0 (8.5) 0.622
  Other regimens, n (%) 1 7.0 (3.6) 2.0 (2.1) 5.0 (5.5) 0.230
Questionnaire assessments
 Depression (BDI score)g 3 0.001*
  Absent/very subtle (≤10 points), n (%) 61 (31.9) 11.0 (11.8) 50.0 (52.6)
  Subtle (11–18 points), n (%) 62 (32.5) 30.0 (32.3) 31.0 (32.6)
  Moderate (19–29 points), n (%) 45 (23.6) 31.0 (33.3) 12.0 (12.6)
  Severe/very severe (≥30 points), n (%) 23 (12.0) 21.0 (22.6) 2.0 (2.1)
 Anxiety (STAI‑Y‑B score)g 3 0.001*
  Absent/very subtle (≤35 points), n (%) 35.0 (18.3) 3.0 (3.2) 32.0 (34.0)
  Subtle (36–45 points), n (%) 57.0 (29.8) 19.0 (20.4) 36.0 (38.3)
  Moderate (46–55 points), n (%) 53.0 (27.8) 34.0 (36.6) 19.0 (20.2)
  Severe/very severe (≥56 points), n (%) 46.0 (24.1) 31.0 (33.3) 6.0 (6.4)
 Lipodystrophy (LDCD score)i 59
  Absent/very subtle (≤9.9 points), n (%) 57.0 (42.2) 28.0 (46.7) 27.0 (38.6) 0.581
  Subtle (10–14.9 points), n (%) 35.0 (25.9) 12.0 (20.0) 22.0 (31.4)
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(Table  1). According to the HOPS score, 62.7, 63.5 and 
35.5% of patients subjectively reported at least one site 
affected by fat hypertrophy or atrophy or both, respec-
tively. Patients and physicians were agree on 80.3% (sub-
stantial agreement, kappa 0.61; p-value 0.001) regarding 
the atrophy and on 79.1% (substantial agreement, kappa 
0.57; p-value 0.001) regarding the hypertrophy (Table 2). 
The agreement regarding the atrophy between the two 
LD tests (HOPS score and LDCD score) was moderate 
(patients and physicians observations; 55.9 and 48.1% 
respectively, p-values <0.001 for both). Regarding hyper-
trophy, the results were not significant (patients and phy-
sicians observations (data not shown).
Mental health, quality of life, and LD stratified by gender
Women were more likely to present signs of depres-
sion or anxiety compared to men (46.0 versus 26.9%; 
p-value = 0.006; and 62.5 versus 42.7%; p-value = 0.006 
for depression and anxiety, respectively) (Table  3). 
Although there was no gender difference in severe LD 
according to the LDCD score (p-value  =  0.082). Men 
seem to be more affected by LA, while women suffered 
mainly from LH according to the HOPS score (Table 3). 
Moreover, women were more likely to score lower on 
quality of life than men (59.5 versus 41.4%, respectively; 
p-value = 0.013).
Factors associated with poor quality of life (QoL)
Among the 188 patients who completed the question-
naire, 93 (49.5%) described a poor quality of life (median 
(IQR): 40.0 (30.0–50.0) with a visual score of <50% [29]. 
Although none of the demographic variables was found 
to be associated with poor quality of life in the multivari-
ate models (M1, M2, Table 4), HIV-related variables, such 
as duration of HIV diagnosis (categorized by ≥10 years) 
and the presence of a detectable viral load (categorized 
by ≥40 copy/mL) both were associated with a poor qual-
ity of life; the shorter the time after HIV diagnosis, the 
worse the quality life (Table 4). Fat atrophy observed by 
patients and physicians was associated with a poor qual-
ity of life in the univariate model, but was no longer sta-
tistically significant in the adjusted analyses. Symptoms 
of depression [M1: OR = 3.62 (95% CI 0.99–13.27); M2: 
OR  =  4.67 (95% CI 1.08–20.31), anxiety features (M1: 
OR  =  7.10 (95% CI 1.99–25.30); M2: OR  =  7.83 (95% 
CI 1.91–32.03)), and severe LD (LDCD) (M1: OR = 6.25 
a Quality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.
b VAT: by CT-scan cross-section of 6 mm, level of L5: intra-abdominal adipose tissue.
c SAT: by CT-scan cross-section of 6 mm, level of L5: extra-abdominal adipose tissue.
d CDC HIV stage: according to CDC Classification System for HIV Infection by the United States Center for Disease Control and Prevention.
e NRTI: Nucleoside reverse transcriptase inhibitors.
f NNRTI: Non-nucleoside reverse transcriptase inhibitors.
g Depression: according to Beck Depression Inventory score by Beck definition (BDI).
h Anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).
i LDCD: Lipodystrophy Case Definition by Carr et al.
* Significant p-value <0.05.
Table 1 continued
N missing All patients Quality of Lifea p-value
Poor (≤50% visual score) High (>50% visual score)
Median (IQR) Median (IQR) Median (IQR)
N = 194 N = 93 N = 95
  Moderate (15–22.9 points), n (%) 12.0 (8.9) 6.0 (10.0) 5.0 (7.1)
  Severe/very severe (≥23 points), n (%) 31.0 (23.0) 14.0 (23.3) 16.0 (22.8)
Table 2 Level of agreement between patients and physicians; HIV Outpatient Study (HOPS) score
Atrophy/hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.
* Significant p-value <0.05.
Patients observation Physicians observation Agreements (%) Kappa p-value Interpretation
N (%) N (%)
N = 167 N = 144
Atrophy 106 (63.5) 71 (49.3) 80.3 0.61 0.001* Substantial
Hypertrophy 106 (62.7) 79 (54.9) 79.1 0.57 0.001* Substantial
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(95% CI:1.33–29.40); M2: OR  =  5.22 (95% CI: 1.07–
25.37)] were all associated with a poor quality of life in 
the univariate model (Table  4). They remained statisti-
cally significant in both multivariate analyses, apart from 
depression, which was significantly associated in the sec-
ond model only (Table 4). No interaction between mental 
health disorders (depression or anxiety) and LD has been 
highlighted within the multivariate logistic regression 
model M2 (data not shown). Finally, we have assumed 
that the two models are correctly specified with no sta-
tistical difference and are in concordance (for M1 and 
M2, respectively: Hosmer–Lemeshow test: p-value: 0.521 
and 0.286; area under the ROC curve 0.847 and 0.863; 
p-value: 0.338).
Discussion
Results of our study indicate a high frequency of LD and 
mental health disorders among HIV-infected men and 
women on successful ART presenting at the LIPO group 
and metabolism day clinic. Almost half of all patients 
considered themselves as suffering from a poor quality of 
life. Severe LD, depression, and anxiety were all associ-
ated with poor quality of life. This high level of LD fre-
quency is partly due because the patients are referred to 
the day clinic by their treating physician.
Through these findings, we demonstrate that the objec-
tive signs of LD, based on a validated score (LDCD) and 
including morphologic data and metabolic values, are 
associated with a decreased quality of life and with the 
presence of mental health disorders. Fat loss observed 
by the patient and the physician (HOPS score) was also 
associated with a poor quality of life, but only in the uni-
variate analysis.
Our results are consistent with several previous stud-
ies. First, some authors have highlighted a poor qual-
ity of life, severe stigma, and lower values in social and 
psychological scores regarding HIV-infected patients 
with or without reported LD [33, 34]. Of note, treat-
ment of mental health disorders improved quality of life 
[33]. Secondly, other studies emphasized an association 
between LD and a negative effect on body image [18, 28, 
34]. Indeed, because of body changes, stigma remains, 
leading to poor self esteem [20]. This leads to social iso-
lation [24], decrease of sexual activity [26], and mental 
health disorders, such as anxiety and depression [35], 
which contribute to poor quality of life [21]. Guaraldi 
et  al. evaluated LD by three scores, i.e., the Multicenter 
AIDS Cohort Study score (MACS)-HOPS-LDCD. The 
results of their study is consistent with our finding that 
LD is related to a poor quality of life [19]. Similar to other 
reports, they observed that the presence of LD can lead 
to ART discontinuation [19, 36, 37]. By contrast, a large 
study showed that individuals suffering from morpholog-
ical alterations, such as LD, maintain a good adherence 
regarding ART [38].
Other studies show discordant results. Quality of life 
scales and psychological questionnaire often change from 
one study to another (i.e.: Health Related QoL (HRQoL) 
[13, 16, 18]; Profil der Lebensqualität Chronischkranker 
(PLC) [19], HIVspecific QoL [32]) and thus complicates 
comparison between the targeted population. In addi-
tion, study objectives vary (i.e.: cosmetic result, antiret-
roviral tolerance, global wellbeing, social isolation) and 
may influence the results. Barata et  al. assessed a psy-
chological questionnaire in outpatients with and without 
LD and found no difference in mental health disorders 
between the two groups [25]. Rajagopalan et  al. found 
similar results regarding quality of life; however, a sub-
group analysis showed that patients with LD, particularly 
homosexual men and patients undergoing psychiatric 
treatment, suffered from a low QoL [22].
LD remains a prevalent adverse event, despite the 
advent of new generation ARV drugs [18]. A recent 
French observational multicenter study showed that 
more than half of all patients on long-term effective ART 
suffer from disturbing and stigmatizing facial lipoat-
rophy. Congruent with reports from other groups, its 
prevalence is around 30% in patients who recently started 
Table 3 Prevalence of mental health alterations and lipod-
ystrophy symptoms by gender 
a Presence of depression: according to Beck Depression Inventory score by Beck 
definition (BDI).
b Presence of anxiety: according to State Trait Anxiety Inventory by Spielberger 
definition (STAI-Y-B).
c Quality of Life Quantitative scale numbered 0%–100 according to the short 
version of EQ-5D-3L score.
d Severe LD: according to LDCD score Lipodystrophy Case Definition by Carr 
et al.
e Atrophy/Hypertrophy observed by patients/physicians: according to HOPS 
score by Lichtenchtein et al.
* Significant p-value <0.05.
Male N (%) Female N (%) p value
Presence of depression  
(BDI score ≥19)a
28 (26.9) 40 (46.0) 0.006*
Presence of anxiety  
(STAI‑Y‑B score ≥46)b
44 (42.7) 55 (62.5) 0.006*
Poor QoL (≤50% visual score)c 43 (41.4) 50 (59.5) 0.013*
Severe LD (LDCD score ≥23 
points)d
21 (28.8) 10 (16.1) 0.082
HOPS score:e
 Atrophy observed by patients 66 (72.5) 40 (52.6) 0.008*
 Atrophy observed by physicians 46 (60.0) 25 (37.3) 0.007*
 Hypertrophy observed by 
patients
47 (51.1) 59 (76.6) 0.001*
 Hypertrophy observed  
by physicians
35 (46.7) 44 (63.8) 0.039*
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their ARV treatment (1–5 years) [39]; the extent to which 
signs of LH reflect the physiological aging process is 
debated [40]. In our cohort, no difference was observed 
in the prevalence of LA and LH among individuals aged 
50 or more and younger patients.
In a recent analysis of 15,275 participants to the Swiss 
HIV Cohort Study, Keiser et al. describe the suicide rate 
in HIV patients from 1998 to 2008. Despite a significant 
decrease rate of suicide between the pre era ARV drugs 
and the late era, suicides are more frequent in HIV pop-
ulation compared to general population [41]. In 62% of 
them, mental health disorders, as depression and anxi-
ety, have been highlighted after the HIV diagnosis [41]. 
HIV infection and its possible impact on mental health 
can be compared to other chronic diseases, such as dia-
betes, asthma, or chronic kidney disease [42–47]. Indeed, 
a similar relationship has been highlighted in a recent 
study showing a major increase of anxiety symptoms as 
well as depression in patients with chronic obstructive 
pulmonary syndrome disease [48]. Interestingly, although 
the symptoms related to pulmonary disease could not be 
improved, recognition of psychological distress by the 
physician led to an enhancement of quality of life [48].
This study shows a complex interplay between quality 
of life, mental health disorders, and signs of LD. Severe 
LD and mental health disorders were all associated with 
a subjective impairment of quality of life. Moreover, 
individuals with a more recent diagnosis (<10  years) or 
those with a detectable viral load (≥40 copy/mL), more 
likely due to insufficient adherence to treatment, had also 
a poor quality of life. Therefore, psychological issues in 
HIV chronic infection is of major importance for daily 
Table 4 Risk factors for poor quality of life
a Quality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.
b BMI: body mass index (bodyweight in kilogram/(height in meter).
c CDC HIV stage: according to CDC Classification System for HIV Infection used by the United States Center for Disease Control and Prevention.
d Severe LD: according to LDCD score Lipodystrophy Case Definition by Carr et al.
e Atrophy/Hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.
f Presence of depression: according to Beck Depression Inventory score by Beck definition (BDI).
g Presence of anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).
* Significant p-value in univariate model <0.2.  
** Significant p-value <0.05.
Poor quality of lifea (≤50% visual score)
Univariate regression M1: p-value ≤0.2 in univariate 
model regression
M2: Clinical risk factors
OR (95%IC) p-values OR (95%IC) p-values OR (95%IC) p-values
Patient characteristics
 Age (≥50 years) 0.62 (0.35–1.11) 0.109* 1.16 (0.38–3.54) 0.794 1.73 (0.52–5.68) 0.365
 Gender (F) 2.09 (1.16–3.74) 0.014* 1.05 (0.35–3.10) 0.930 1.49 (0.46–4.78) 0.502
 BMI (≥30 kg/m2)b 0.90 (0.53–2.33) 0.828 – – 1.01 (0.14–7.18) 0.988
 Triglycerides (≥2.0 mmol/L) 0.62 (0.33–1.16) 0.135* 0.60 (0.19–1.94) 0.397
HIV characteristics
 HIV duration (≥ 10 years) 0.43 (0.21–0.92) 0.030* 0.14 (0.03–0.79) 0.026** 0.10 (0.01–0.63) 0.014**
 CDC HIV stage (B&C)c 1.52 (0.84‑–2.77) 0.170* 0.81 (0.27–2.39) 0.697 0.95 (0.30–3.00) 0.936
 CD4 (≤300 cells/mm3) 0.57 (0.20–1.64) 0.300 – – 0.09 (0.01–1.04) 0.054
 HIV viral load (≥40 copy/mL) 2.55 (1.04–6.2) 0.039* 10.4 (1.73–2.55) 0.011** 10.39 (1.79–60.16) 0.009**
 Current use of efavirenz 1.46 (0.69–3.06) 0.316 – –
Questionnaire assessments
 Severe LD (LDCD score ≥23 points)d 1.02 (0.45–2.33) 0.949 6.25 (1.33–29.40) 0.020** 5.22 (1.07–25.37) 0.040**
 HOPS score:e
  Atrophy observed by patients 0.51 (0.27–0.99) 0.047* 0.49 (0.12–2.07) 0.334 0.27 (0.05–1.40) 0.120
  Atrophy observed by physicians 0.51 (0.26–1.00) 0.051* 1.13 (0.30–4.26) 0.860 1.47 (0.37–5.84) 0.580
  Hypertrophy observed by patients 1.37 (0.73–2.58) 0.325 – – 0.50 (0.10–2.49) 0.396
  Hypertrophy observed by physicians 0.75 (0.38–1.47) 0.400 – – 0.56 (0.13–2.39) 0.438
  Presence of depression (BDI score ≥19)f 7.33 (3.64–14.77) 0.001* 3.62 (0.99–13.27) 0.053 4.67 (1.08–20.31) 0.040**
  Presence of anxiety (STAI‑Y‑B score ≥46)g 8.44 (4.37–16.30) 0.001* 7.10 (1.99–25.30) 0.003** 7.83 (1.91–32.03) 0.004**
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constraints associated with the disease, adherence to 
therapy, and quality of life.
Women were more likely to express signs of depression 
and anxiety as found in other studies [49, 50]. Depressive 
symptoms are more than two-fold than those reported 
in the general population, while the number of men and 
women patients with anxiety symptoms is multiplied by 
2.5 [51]. Men were more likely addressed to our group for 
LA and women for LH. We may speculate that the accept-
ability of LA and LH phenotype is gender-influenced.
Our study has some limitations. First, we used a modi-
fied quality of life score. This scale registers the self-esti-
mation of the patient within a very specific timeframe. 
For this reason, a various number of independent vari-
ables can interfere with this estimate. We arbitrarily 
defined poor quality of life as between 0–50 and good 
quality of life between 51–100 and these thresholds 
could be challenged. However, this measure is simple to 
evaluate, and easily repeatable. Moreover, the QoL score 
that we used in our study has the advantage to be used 
directly during the clinical interview and measure syn-
thetically the psychic pain in a biopsychosocial situation. 
As the validated Visual Analog Scale (VAS) largely used 
for pain appreciation, our QoL scale measure a subjec-
tive definition. Secondly, LD assessment remains difficult 
because of the lack of a gold standard definition. How-
ever, we consider that the use of two different scores, one 
based on the physician and patient perceptions and the 
other based on objective features, allowed us to capture 
with sufficient precision the prevalence and the severity 
of LD in this population. We were able to assess LD with 
great precision, using multiple and routinely-performed 
tools during the patient one-day visits to the day hospi-
tal. These included 191 of validated questionnaires, rep-
resenting 98.5% of the patients included in the cohort, 
and 135 imaging (69.6%) (CT and DXA scans), as well 
as biological values, which are all features related to the 
LD. Regarding the HOPS score, there was good concord-
ance between physician and patient assessments for fat 
atrophy and hypertrophy. Moreover, although the study 
population represented selected individuals referred 
by their practicing physician, it included both men and 
women of diverse ethnicity, thus making our results more 
consistent.
Conclusions
The majority of the HIV-infected patients seen in the 
metabolic clinic in Geneva describe, at least, one body 
site affected by LA or LH and are diagnosed with LD 
regarding the LDCD score. Depression as well as anxi-
ety feature are also very frequent in our studied popula-
tion, and, with the presence of LD, are related to a poor 
quality of life, leading to psycho-social consequences. 
Mental health and a simple score for quality of life 
should be routinely assessed among HIV-infected indi-
viduals, including those on effective ART, in order to 
recognize early signs and symptoms of psychological 
distress and to help patients have better outcomes in 
their daily life.
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